## **EDITORIAL**



## A call for improved reporting of human islet characteristics in research articles

Vincent Poitout <sup>1,2</sup> • Leslie S. Satin <sup>3,4</sup> • Steven E. Kahn <sup>5</sup> • Doris A. Stoffers <sup>6,7</sup> • Piero Marchetti <sup>8</sup> • Maureen Gannon <sup>9</sup> • C. Bruce Verchere <sup>10,11,12</sup> • Kevan C. Herold <sup>13</sup> • Martin G. Myers Jr <sup>3,14</sup> • Sally M. Marshall <sup>15</sup>

Received: 8 November 2018 / Accepted: 12 November 2018 / Published online: 14 December 2018 © The Author(s) 2018

**Keywords** Diabetes · Human · Insulin · Islets · Pancreas · Reporting · Research · Resource · Rigour · Transparency · Unique identifier

The increased availability of isolated human islets for diabetes research and the implementation of islet distribution programmes in several countries worldwide have been driving forces behind the rapidly expanding number of scientific reports on studies using human islets. In this issue of *Diabetologia*, Hart and Powers [1] not only review the progress made in human islet research, made possible through their greater availability, but also identify the challenges associated with their use. These include the wide functional heterogeneity observed between islet preparations and the highly variable (and often inadequate) reporting of human islet characteristics in the scientific literature.

Many factors contribute to the functional heterogeneity observed between human islet preparations. These include differences in donor characteristics (age, sex, ethnic background, health status prior to death and cause of death); differences in pancreas procurement (isolation centre, islet handling,

Sally M. Marshall is Editor-in-Chief of *Diabetologia*, and Martin G. Myers Jr is Editor-in-Chief of *Diabetes*.

Vincent Poitout and Leslie S. Satin are joint first authors, and Martin G. Myers Jr and Sally M. Marshall are joint senior authors.

Vincent Poitout, Steven E. Kahn, Piero Marchetti and C. Bruce Verchere are Associate Editors for *Diabetologia*. Leslie S. Satin, Doris A. Stoffers, Maureen Gannon and Kevan C. Herold are Associate Editors for *Diabetes*.

This Editorial is being simultaneously published in *Diabetologia* and *Diabetes*.

∨ Vincent Poitout vincent.poitout@umontreal.ca

Extended author information available on the last page of the article

estimated purity and viability); warm and cold ischaemia times; and tissue culture [1]. All of these factors influence, to varying degrees, the morphology and function of the islets as investigated in the laboratory [2–5]. For example, out of the 13 islet preparations from donors without diabetes for which islet cell composition is provided in the Human Pancreas Analysis Program PancDB database of the Human Islet Research Network [6], the relative proportion of islet beta cells ranged from 28.5% to 75.8% of the total endocrine cell population (e.g. alpha, beta, delta and epsilon cells).

Hart and Powers [1] surveyed 241 papers reporting the use of isolated human islets, published over a 4 year period, and found large discrepancies in the type of information provided by authors regarding the characteristics of the islets used in these studies. Over half of them did not provide any functional data. In addition, the experimental approaches used to measure human islet function lacked any kind of standardisation.

Based on their analysis and their own experience, the authors call on the 'human islet research ecosystem', which includes organ procurement organisations, islet isolation and phenotyping centres, islet distribution programmes, investigators, funding agencies and scientific journals, to 'develop more holistic, nuanced and sophisticated standards and criteria for assessing and reporting critical characteristics of human islets used for research' [1]. They further propose a list of actions to be taken by each member of this ecosystem towards better standardisation and provide a possible template for providing key information on human islet preparations reported in research papers.

As leading scientific journals in the field of islet biology and pathophysiology, *Diabetologia* and *Diabetes* endorse the general objectives set forth by Hart and Powers. We believe that these objectives will facilitate comparisons among studies using isolated human islets by improving the reporting and, to



210 Diabetologia (2019) 62:209–211

the extent possible, standardisation of the preparations and methods used by individual laboratories. Such objectives are aligned with the current emphasis placed on scientific rigour and reproducibility in research by a number of major funding organisations (including the US National Institutes of Health and the Canadian Institutes of Health Research) and might even be extended, at some point, to other human tissues that are used in biomedical research.

Furthermore, knowledge of the detailed characteristics of the islets employed in the increasing number of studies that involve global, unbiased genetic profiling at the single-cell level (e.g. [7–10]) will be especially important to permit comparisons among the large reference databases that result from these types of studies.

We recognise that this is an ambitious objective that will require a stepwise approach. As a first step, Diabetologia and Diabetes have created a modified version of the checklist suggested by Hart and Powers [1]. This checklist will be required at the point of submission for any manuscripts that include human islet data (http://diabetologia-journal.org/for-authors/instructionsto-authors/#reporting-guidelines) and will be made available with the published paper. A minimum set of mandatory islet characteristics are listed, as well as others that are recommended to report if they are available. Authors will be required to provide, in table form, the source, isolation centre and unique identifier number for each islet preparation, together with the age, sex, BMI and HbA<sub>1c</sub> (or other measure of glucose control) of the donor, and whether s/he had diabetes or not. These data will be reported in such a manner that protects the identity of the donor. While we will not make it mandatory at the present time, we encourage the inclusion of additional data to even better characterise the human islets employed for experimentation, including the cause of donor death, measurements of islet purity and viability, functional measures (e.g. glucosestimulated insulin secretion), ischaemia duration and culture time.

As editors of *Diabetologia* and *Diabetes*, we consider that making these basic metadata available is a good starting point for improving the reproducibility and transparency of the human islet studies reported in our journals.

We hope that the islet community will provide feedback to help us refine and expand the checklist. We believe that authors can more fully document their human islet preparations without this being an undue burden. We are cognisant that not every investigator or distribution centre will have access to this much information and we are also aware of privacy restrictions, protected by law, that may prevent the sharing of some medical metadata. This initiative is just a start, but one that we hope will improve human islet research and further advance our field.

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

**Contribution statement** All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References

- Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia. https://doi.org/10.1007/s00125-018-4772-2
- Lyon J, Manning Fox JE, Spigelman AF et al (2016) Researchfocused isolation of human islets from donors with and without diabetes at the Alberta Diabetes Institute Islet Core. Endocrinology 157(2):560–569. https://doi.org/10.1210/en.2015-1562
- Henquin JC (2018) Influence of organ donor attributes and preparation characteristics on the dynamics of insulin secretion in isolated human islets. Physiol Rep 6(5):e13646. https://doi.org/10.14814/phy2.13646
- Kayton NS, Poffenberger G, Henske J et al (2015) Human islet preparations distributed for research exhibit a variety of insulinsecretory profiles. Am J Physiol Endocrinol Metab 308(7):E592– E602. https://doi.org/10.1152/ajpendo.00437.2014
- Westacott MJ, Farnsworth NL, St Clair JR et al (2017) Agedependent decline in the coordinated [Ca<sup>2+</sup>] and insulin secretory dynamics in human pancreatic islets. Diabetes 66(9):2436–2445. https://doi.org/10.2337/db17-0137
- Human Pancreas Analysis Program. For Investigators. Available from https://hpap.pmacs.upenn.edu/explore. Accessed 14 November 2018
- Li J, Klughammer J, Farlik M et al (2015) Single-cell transcriptomes reveal characteristic features of human pancreatic islet cell types. EMBO Rep 178–187. https://doi.org/10.15252/ embr.201540946
- Xin Y, Kim J, Okamoto H et al (2017) RNA sequencing of single human islet cells reveals type 2 diabetes genes. Cell Metab 26:1–8
- Segerstolpe A, Palasantza A, Eliasson P et al (2016) Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab 24:1–15
- Wang YJ, Schug J, Won KJ et al (2016) Single-cell transcriptomics of the human endocrine pancreas. Diabetes 65(10):3028–3038. https://doi.org/10.2337/db16-0405



Diabetologia (2019) 62:209–211 211

## **Affiliations**

Vincent Poitout <sup>1,2</sup> • Leslie S. Satin <sup>3,4</sup> • Steven E. Kahn <sup>5</sup> • Doris A. Stoffers <sup>6,7</sup> • Piero Marchetti <sup>8</sup> • Maureen Gannon <sup>9</sup> • C. Bruce Verchere <sup>10,11,12</sup> • Kevan C. Herold <sup>13</sup> • Martin G. Myers Jr <sup>3,14</sup> • Sally M. Marshall <sup>15</sup>

- Montreal Diabetes Research Center, Centre de recherche du centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue Saint-Denis, Office R05-406, Montréal, QC H2X 0A9, Canada
- Department of Medicine, University of Montreal, Montreal, QC, Canada
- <sup>3</sup> Brehm Diabetes Center, University of Michigan, Ann Arbor, MI, USA
- Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA, USA
- Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- BC Children's Hospital Research Institute, Vancouver, BC, Canada
- Department of Surgery, University of British Columbia, Vancouver, BC, Canada
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Department of Immunobiology and Internal Medicine, Yale University, New Haven, CT, USA
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
- Institute of Cellular Medicine, Faculty of Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

